Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19
Coronavirus disease 2019 (COVID-19) is a respiratory tract disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With the complexity of multimorbidity in Indonesia, it is crucial to find another line of antiviral for COVID-19. This article aims to review two antivirals, mol...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Interna Publishing
2023-01-01
|
| Series: | Acta Medica Indonesiana |
| Subjects: | |
| Online Access: | http://www.actamedindones.org/index.php/ijim/article/view/2115 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850113286243090432 |
|---|---|
| author | Samuel Theodorus Sutanto Robert Sinto Adeline Pasaribu Sharifah Shakinah |
| author_facet | Samuel Theodorus Sutanto Robert Sinto Adeline Pasaribu Sharifah Shakinah |
| author_sort | Samuel Theodorus Sutanto |
| collection | DOAJ |
| description | Coronavirus disease 2019 (COVID-19) is a respiratory tract disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With the complexity of multimorbidity in Indonesia, it is crucial to find another line of antiviral for COVID-19. This article aims to review two antivirals, molnupiravir and nirmatrelvir/ritonavir, that have been studied extensively in treating COVID-19 with promising results, and their availability in Indonesia. Molnupiravir and nirmatrelvir/ritonavir are two of many repurposed drugs in clinical trials, which have been reported to have a mechanism in quick clearance of SARS-CoV-2, reduction in viral load, and fast symptoms recovery time in phase 1 and 2 clinical trials. Phase 2/3 clinical study in COVID-19 patients without any indication for hospitalization showed that molnupiravir and nirmatrelvir/ritonavir significantly reduced the risk of hospitalization and death.
|
| format | Article |
| id | doaj-art-57839fb5b73941bb85a7b0f02baa8ee4 |
| institution | OA Journals |
| issn | 0125-9326 2338-2732 |
| language | English |
| publishDate | 2023-01-01 |
| publisher | Interna Publishing |
| record_format | Article |
| series | Acta Medica Indonesiana |
| spelling | doaj-art-57839fb5b73941bb85a7b0f02baa8ee42025-08-20T02:37:12ZengInterna PublishingActa Medica Indonesiana0125-93262338-27322023-01-01544Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19Samuel Theodorus Sutanto0Robert Sinto1Adeline Pasaribu2Sharifah Shakinah3Faculty of Medicine, Universitas Kristen Krida Wacana, Jakarta, IndonesiaDivision of Tropical and Infectious Diseases, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia.Division of Tropical and Infectious Diseases, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia.Division of Tropical and Infectious Diseases, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia.Coronavirus disease 2019 (COVID-19) is a respiratory tract disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With the complexity of multimorbidity in Indonesia, it is crucial to find another line of antiviral for COVID-19. This article aims to review two antivirals, molnupiravir and nirmatrelvir/ritonavir, that have been studied extensively in treating COVID-19 with promising results, and their availability in Indonesia. Molnupiravir and nirmatrelvir/ritonavir are two of many repurposed drugs in clinical trials, which have been reported to have a mechanism in quick clearance of SARS-CoV-2, reduction in viral load, and fast symptoms recovery time in phase 1 and 2 clinical trials. Phase 2/3 clinical study in COVID-19 patients without any indication for hospitalization showed that molnupiravir and nirmatrelvir/ritonavir significantly reduced the risk of hospitalization and death. http://www.actamedindones.org/index.php/ijim/article/view/2115antiviralCOVID-19molnupiravirnirmatrelvir/ritonavirSARS-CoV-2 |
| spellingShingle | Samuel Theodorus Sutanto Robert Sinto Adeline Pasaribu Sharifah Shakinah Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19 Acta Medica Indonesiana antiviral COVID-19 molnupiravir nirmatrelvir/ritonavir SARS-CoV-2 |
| title | Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19 |
| title_full | Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19 |
| title_fullStr | Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19 |
| title_full_unstemmed | Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19 |
| title_short | Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19 |
| title_sort | molnupiravir and nirmatrelvir ritonavir the new available antiviral options for covid 19 |
| topic | antiviral COVID-19 molnupiravir nirmatrelvir/ritonavir SARS-CoV-2 |
| url | http://www.actamedindones.org/index.php/ijim/article/view/2115 |
| work_keys_str_mv | AT samueltheodorussutanto molnupiravirandnirmatrelvirritonavirthenewavailableantiviraloptionsforcovid19 AT robertsinto molnupiravirandnirmatrelvirritonavirthenewavailableantiviraloptionsforcovid19 AT adelinepasaribu molnupiravirandnirmatrelvirritonavirthenewavailableantiviraloptionsforcovid19 AT sharifahshakinah molnupiravirandnirmatrelvirritonavirthenewavailableantiviraloptionsforcovid19 |